How many insider trades does FilingIQ track for ANRO?

FilingIQ tracks 37 Form 4 insider transactions for ANRO (Alto Neuroscience, Inc.), covering filings from Feb 6, 2024 onwards. 7 of those were filed in the last 90 days.

Are ANRO insiders net buyers or net sellers?

Across the full Form 4 history for ANRO, 9 transactions (24%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ANRO insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ANRO in?

Alto Neuroscience, Inc. (ANRO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $555.62M.

ANRO insider trading

Healthcare

Alto Neuroscience, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

24% / 0%

Market cap

$555.62M

About Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Company website: www.altoneuroscience.com

ANRO insider activity at a glance

FilingIQ has scored 37 insider transactions for ANRO since Feb 6, 2024. The most recent filing in our index is dated May 12, 2026.

Across the full history, 9 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ANRO insider trades is 49.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ANRO trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for ANRO?: FilingIQ tracks 37 Form 4 insider transactions for ANRO (Alto Neuroscience, Inc.), covering filings from Feb 6, 2024 onwards. 7 of those were filed in the last 90 days.
Are ANRO insiders net buyers or net sellers?: Across the full Form 4 history for ANRO, 9 transactions (24%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ANRO insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ANRO in?: Alto Neuroscience, Inc. (ANRO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $555.62M.

Methodology & sources

Every ANRO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.